Ok Satish Reddy, Chairman Dr Reddy’s Laboratories
India ought to lead the world in selling options to animal testing in drug discovery and framing non-animal methodologies, Ok Satish Reddy, Chairman, Dr Reddy’s Laboratories.
He was talking at a press convention to announce the findings of a report, `Panorama Evaluation on Options to Animal Testing for Drug Growth in India”, collectively ready by Humane World for Animals India, DBT-InSTEM, Animal Regulation and Coverage Community and Dr Reddy’s Laboratories on Thursday.
Reddy stated drug discovery was a journey with new methodologies sometimes. The Indian regulatory framework also needs to be ready in NAMs. The CDSCO has already begun the journey, and the required infrastructure and staffing may very well be put in place going ahead, he added.
Citing the report’s findings, Alokparna Sengupta, Managing Director, Humane World for Animals India, stated {that a} central non-animal methodology company and validation centre with a related database ought to be established. It additionally beneficial a multi-stakeholder consortium for collaboration amongst all stakeholders, and the institution of centres of excellence for infrastructure, coaching, and skilling.
The report additionally prompt accelerated alternative of animal-based pyrogen testing by selling validated options such because the Monocyte Activation Check (MAT) and recombinant Issue C (rFC) assay, supported by coaching, standardisation, and improved reagent availability.
On this trendy age, we’ve got human cell-based and computational fashions that can mirror human biology way more precisely, decreasing the danger of drug failures. These rising applied sciences can save the lives of animals, revolutionise public well being, and support in faster and cost-effective drug improvement,’’ she stated.
Deepak Sapra, CEO-API & Providers, Dr Reddy’s Laboratories, and main drug-makers in India, together with Dr Reddy’s, had been eager to undertake NAMs and are working with different gamers, together with Biocon, Cipla and Solar Pharma.
New applied sciences, which can be found now, together with organoids, computational instruments, cardiac and liver fashions, would assist in the journey in the direction of NAMs, he stated, including: “Dr Reddy’s is actively integrating NAMs in the processes and can additional push them,’’ he stated.
In response to Niazi, generics, biologicals, and biosimilars wouldn’t require any animal testing. The adoption of NAMs would cut back drug improvement prices and save time, he stated.
Historically, animal fashions have been central to preclinical testing. Nonetheless, species-specific variations in physiology and genetics restrict their potential to foretell human outcomes. Solely round 10% of medicine coming into Part I trials in the end obtain regulatory approval, resulting in larger prices, longer timelines, and the lack of probably helpful therapies, he stated.
Nonetheless, animal testing can’t be averted for chemical medicine and different new molecules for the time being and methods and means ought to be explored on this entrance.
Revealed on February 5, 2026
Source link
#India #lead #nonanimal #testingbased #methodologies #Reddys #Chairman #Satish #Reddy
